The FDA has authorized DreaMed Diabetes, the company that manufactures personalized management solutions for people with diabetes, to issue AI-powered technology for insulin management.
The company’s decision support application, dubbed DreaMed Advisor Pro, will help those with type 1 diabetes. The new technology uses insulin pump therapy together with glucose meters or continuous glucose sensors.
Close to 1.3 million Americans suffer from type 1 diabetes, of which 200000 are below the age of 20. By the year 2050, it is expected that this number will rise to 5 million in America alone. People with type 1 diabetes have to take insulin shots to keep their blood levels in check.
About 25 percent of patients in the U.S who have type 1 diabetes use continuous glucose sensors as well as insulin pumps, while 40 percent use glucose meters and insulin pumps to keep blood glucose under control.
The cloud-based tool Advisor Pro comes up with insulin recommendations by carrying out analysis of data collected by insulin sensors and meters.
This technology, which was awarded a European CE prize, relays personal data in real-time to a health care provider for them to work out how to optimize individual pumps. Through such personalized care, a person with type 1 diabetes will be able to receive correct insulin doses from a GP in the even there are few consultants at hand. Implementation of this technology requires analysis of a huge chunk of data.
Data collection is the first step in the process of improving insulin. DreaMed then analyses this data and offer recommendations to GPs on the appropriate therapy schedule for a patient.
The recommendations also help to make GPs much more accurate and efficient when interacting with the data collected by sensors. That way, they are able to intervene in a timely manner, optimize treatment and improve a patient’s metabolic activity.